看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。5 |% Y# ^5 k# a7 \+ k
% \( s/ p1 L, {+ O0 C
& [5 k p7 _) h8 `- q6 |# }Currently available feasibility data for possible combination strategies. + N( q$ ~- g/ h$ O6 O
————————————————————————————————; b( k' p7 C( P+ b0 [, H) x
Combination Feasibility according to preliminary data
8 J8 d+ J" W6 N9 h4 e——————————————————————————————————- U/ W* O/ B3 q3 O4 M4 \( V
Bevacizumab + sorafenib Yes, reduced dose ( D. C) K/ i, T$ L9 c
Bevacizumab + sunitinib† No
* E' ^0 T6 y" t0 VBevacizumab + temsirolimus Yes K, U. {, o% S# S5 o
Bevacizumab + everolimus Yes
9 S5 b, M% P. QSorafenib + sunitinib ? 3 G$ p" l$ q- @0 T* _& a
Sorafenib + temsirolimus Yes, reduced dose
, ]: k0 Z8 p8 L9 [) n, S# G, dSorafenib + everolimus Yes, reduced dose % Q2 Y9 s' a: C- Y( }5 m- b( _
Sunitinib + temsirolimus† No
$ ~# p3 J9 p1 O+ T: vSunitinib + everolimus ? ) ^. W4 L3 L2 h
Temsirolimus + everolimus ?
3 q) R$ n% c* y u1 \————————————————————
0 q+ y2 w0 l& ]0 U3 l/ R: r0 V. h†Led to US FDA warning.
7 n) p% C. l& S/ s6 o?: As yet unattempted combination.% O, {. C# X" l) _ X
|
显身卡
